Grail Inc
NASDAQ:GRAL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Litian Pictures Holdings Ltd
HKEX:9958
|
CN |
|
First Sensor AG
XETRA:SIS
|
DE |
|
C
|
Chongqing Pharscin Pharmaceutical Co Ltd
SZSE:002907
|
CN |
|
S
|
State Grid Yingda Co Ltd
SSE:600517
|
CN |
|
I
|
iSoftStone Information Technology Group Co Ltd
SZSE:301236
|
CN |
Grail Inc
Total Current Liabilities
Grail Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Grail Inc
NASDAQ:GRAL
|
Total Current Liabilities
$79.7m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$43.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$11.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$25.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$4.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
|
Grail Inc
Glance View
Grail Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Menlo Park, California and currently employs 1,370 full-time employees. The company went IPO on 2024-06-12. GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. The company is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.
See Also
What is Grail Inc's Total Current Liabilities?
Total Current Liabilities
79.7m
USD
Based on the financial report for Dec 31, 2025, Grail Inc's Total Current Liabilities amounts to 79.7m USD.
What is Grail Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
12%
Over the last year, the Total Current Liabilities growth was 4%. The average annual Total Current Liabilities growth rates for Grail Inc have been -16% over the past three years , 12% over the past five years .
